Dr. Reddy's Laboratories is currently trading at Rs. 4008.55, up by 3.80 points or 0.09% from its previous closing of Rs. 4004.75 on the BSE.
The scrip opened at Rs. 4030.00 and has touched a high and low of Rs. 4044.90 and Rs. 3994.00 respectively. So far 14166 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.
Last one week high and low of the scrip stood at Rs. 4127.20 and Rs. 3954.20 respectively. The current market cap of the company is Rs. 66484.06 crore.
The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.
Dr. Reddy's Laboratories has launched Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food & Drug Administration (USFDA). The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1508.15 |
Dr. Reddys Lab | 6290.55 |
Cipla | 1412.15 |
Zydus Lifesciences | 948.00 |
Lupin | 1621.35 |
View more.. |